• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NOX
Click for more information
0.00% 9.9¢

NOXOPHARM LIMITED - Announcements

Market Cap $29.22M  ! watchlist Created with Sketch. Add to my watchlist

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel... Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
NOX KZA: Kazia Therapeutics and NoxopharmPRICE SENSITIVE27/12/17
NOX EOY Guidance on 2018 NOX66 Clinical Development StrategyPRICE SENSITIVE21/12/17
NOX Section 708 Certificate19/12/17
NOX Appendix 3B19/12/17
NOX Response to ASX Price QueryPRICE SENSITIVE14/12/17
NOX Appendix 3B12/12/17
NOX Change of Registered Office11/12/17
NOX Section 708 Certificate07/12/17
NOX Appendix 3B07/12/17
NOX NOX Open Briefing Corporate Presentation06/12/17
NOX Compassionate use of NOX66 in Patients04/12/17
NOX Nyrada Inc Opens Capital Raise - Memorandum ReleasedPRICE SENSITIVE01/12/17
NOX Change of Director's Interest Notice - PM29/11/17
NOX Change of Director's Interest Notice - ID29/11/17
NOX Appendix 3B29/11/17
NOX Webcast of NOX 2017 AGM29/11/17
NOX NYX-104 delivers Key Proof-of-Concept in Stroke Animal ModelPRICE SENSITIVE29/11/17
NOX Invitation to Open Briefing28/11/17
NOX Results of Meeting27/11/17
NOX AGM Presentations27/11/17
NOX Clarification of Incorrect InformationPRICE SENSITIVE23/11/17
NOX Trading HaltPRICE SENSITIVE23/11/17
NOX NRT: Kazia clarifies media report22/11/17
NOX NOX 2017 AGM Webcast21/11/17
NOX Completion of Transfer of Shares to Nyrada Inc21/11/17
NOX Promising Interim Clinical Data for NOX66PRICE SENSITIVE20/11/17
NOX Trading HaltPRICE SENSITIVE17/11/17
NOX 1st Patient treated in Lupin Study at St Vincent's HospitalPRICE SENSITIVE16/11/17
NOX Section 708 Certificate15/11/17
NOX Appendix 3B15/11/17
NOX NOX making three presentations at COSA13/11/17
NOX Section 708 Certificate07/11/17
NOX Appendix 3B07/11/17
NOX Results of Meeting06/11/17
NOX EGM Presentations06/11/17
NOX UNSW collaboration confirms drug designed for stroke victimsPRICE SENSITIVE03/11/17
NOX Appendix 4C - quarterlyPRICE SENSITIVE30/10/17
NOX Notice of Annual General Meeting/Proxy Form26/10/17
NOX Annual Report to shareholders26/10/17
NOX Corporate Governance Statement - Appendix 4G26/10/17
NOX Corporate Governance Statement - 201726/10/17
NOX Update - General Meeting Agenda23/10/17
NOX October 2017 Open Briefing Corporate Presentation19/10/17
NOX Invitation to Open Briefing13/10/17
NOX Establishment of Nyrada Inc. - Extraordinary General Meeting04/10/17
NOX Australian NOX66 - Radiotherapy Study OpensPRICE SENSITIVE27/09/17
NOX Establishment of Nyrada Inc.PRICE SENSITIVE25/09/17
NOX Positive Clinical Outcomes for NOX66 at ESMO ConferencePRICE SENSITIVE12/09/17
NOX Change in substantial holding07/09/17
NOX Change in substantial holding06/09/17
NOX Placement completed App 3B, s708 Notice, LR7.1A4(b) Notice04/09/17
NOX NOX CEO Interview explains recent Brain Cancer Announcement04/09/17
NOX Appendix 4E and Audited Financial StatementsPRICE SENSITIVE31/08/17
NOX Corporate Governance Statement - Appendix 4G31/08/17
NOX Corporate Governance Statement31/08/17
NOX Important Brain Cancer Findings for NOX66 ProgramPRICE SENSITIVE29/08/17
NOX Reinstatement to Official QuotationPRICE SENSITIVE24/08/17
NOX Noxopharm raises $5.5 million to advance clinical programPRICE SENSITIVE24/08/17
NOX Suspension from Official QuotationPRICE SENSITIVE23/08/17
NOX Trading Halt Request21/08/17
NOX Trading HaltPRICE SENSITIVE21/08/17
NOX NOX Corporate Presentation ahead of Conference08/08/17
NOX Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
NOX NOX Research Report prepared by APP Securities27/07/17
NOX CEO Interview with FNN - Singapore and HK Roadshow25/07/17
NOX New Corporate Presentation25/07/17
NOX Noxopharm provides update on NOX66 Clinical Trial ProgramPRICE SENSITIVE06/07/17
NOX Idronoxil data provides hope to treat secondary brain cancerPRICE SENSITIVE19/06/17
NOX NOX66 confirmed Non-Toxic. Trial Cleared for Full EnrolmentPRICE SENSITIVE05/06/17
NOX New Corporate Presentation30/05/17
NOX St Vincents Cancer Study to Commence-NOX66 and RadiotherapyPRICE SENSITIVE29/05/17
NOX NOX makes strategic commitment to treatment of rare cancersPRICE SENSITIVE24/05/17
NOX Noxopharm Mid Year Investor Briefings18/05/17
NOX Market Guidance for Next Six MonthsPRICE SENSITIVE02/05/17
NOX Appendix 4C - quarterlyPRICE SENSITIVE27/04/17
NOX FNN Interview with NOX CEO Explaining Idronoxil-C Discovery10/04/17
NOX NOX Files Patent Application on 'Smart' IdronoxilPRICE SENSITIVE10/04/17
NOX Appendix 3B03/04/17
NOX NOX and Monash Uni Collaboration Receives Federal GrantPRICE SENSITIVE27/03/17
NOX Noxopharm and UNSW combine on stroke projectPRICE SENSITIVE16/03/17
NOX Gold Coast Qld Mid-Year Briefing Details10/03/17
NOX Notification of Release of Restricted Securities Escrow07/03/17
NOX NOX researching rare Abscopal ResponsePRICE SENSITIVE03/03/17
NOX Appendix 4D and Half Year AccountsPRICE SENSITIVE24/02/17
NOX NOX Presentation and Interview ASX The CEO Sessions24/02/17
NOX Updated Share Trading Policy23/02/17
NOX ASX CEO Presentation Feb 201721/02/17
NOX Upcoming Events and Presentations15/02/17
NOX Change of Principal Place of Business03/02/17
NOX Brain Cancer Study CommencesPRICE SENSITIVE01/02/17
NOX First NOX66 Clinical Trial to CommencePRICE SENSITIVE31/01/17
NOX Appendix 4C - quarterlyPRICE SENSITIVE30/01/17
NOX Appointment of New Company Secretary16/01/17
NOX Appendix 3B09/01/17
NOX Change in substantial holding20/12/16
NOX Change of Director's Interest Notice - ID20/12/16
NOX Change of Director's Interest Notice - GK20/12/16
NOX Market Capitalisation - further update20/12/16
NOX Appendix 3B20/12/16
NOX Market Capitalisation Update19/12/16
NOX KZA: Kazia Therapeutics and Noxopharm
27/12/17PRICE SENSITIVE
NOX EOY Guidance on 2018 NOX66 Clinical Development Strategy
21/12/17PRICE SENSITIVE
NOX Section 708 Certificate
19/12/17
NOX Appendix 3B
19/12/17
NOX Response to ASX Price Query
14/12/17PRICE SENSITIVE
NOX Appendix 3B
12/12/17
NOX Change of Registered Office
11/12/17
NOX Section 708 Certificate
07/12/17
NOX Appendix 3B
07/12/17
NOX NOX Open Briefing Corporate Presentation
06/12/17
NOX Compassionate use of NOX66 in Patients
04/12/17
NOX Nyrada Inc Opens Capital Raise - Memorandum Released
01/12/17PRICE SENSITIVE
NOX Change of Director's Interest Notice - PM
29/11/17
NOX Change of Director's Interest Notice - ID
29/11/17
NOX Appendix 3B
29/11/17
NOX Webcast of NOX 2017 AGM
29/11/17
NOX NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model
29/11/17PRICE SENSITIVE
NOX Invitation to Open Briefing
28/11/17
NOX Results of Meeting
27/11/17
NOX AGM Presentations
27/11/17
NOX Clarification of Incorrect Information
23/11/17PRICE SENSITIVE
NOX Trading Halt
23/11/17PRICE SENSITIVE
NOX NRT: Kazia clarifies media report
22/11/17
NOX NOX 2017 AGM Webcast
21/11/17
NOX Completion of Transfer of Shares to Nyrada Inc
21/11/17
NOX Promising Interim Clinical Data for NOX66
20/11/17PRICE SENSITIVE
NOX Trading Halt
17/11/17PRICE SENSITIVE
NOX 1st Patient treated in Lupin Study at St Vincent's Hospital
16/11/17PRICE SENSITIVE
NOX Section 708 Certificate
15/11/17
NOX Appendix 3B
15/11/17
NOX NOX making three presentations at COSA
13/11/17
NOX Section 708 Certificate
07/11/17
NOX Appendix 3B
07/11/17
NOX Results of Meeting
06/11/17
NOX EGM Presentations
06/11/17
NOX UNSW collaboration confirms drug designed for stroke victims
03/11/17PRICE SENSITIVE
NOX Appendix 4C - quarterly
30/10/17PRICE SENSITIVE
NOX Notice of Annual General Meeting/Proxy Form
26/10/17
NOX Annual Report to shareholders
26/10/17
NOX Corporate Governance Statement - Appendix 4G
26/10/17
NOX Corporate Governance Statement - 2017
26/10/17
NOX Update - General Meeting Agenda
23/10/17
NOX October 2017 Open Briefing Corporate Presentation
19/10/17
NOX Invitation to Open Briefing
13/10/17
NOX Establishment of Nyrada Inc. - Extraordinary General Meeting
04/10/17
NOX Australian NOX66 - Radiotherapy Study Opens
27/09/17PRICE SENSITIVE
NOX Establishment of Nyrada Inc.
25/09/17PRICE SENSITIVE
NOX Positive Clinical Outcomes for NOX66 at ESMO Conference
12/09/17PRICE SENSITIVE
NOX Change in substantial holding
07/09/17
NOX Change in substantial holding
06/09/17
NOX Placement completed App 3B, s708 Notice, LR7.1A4(b) Notice
04/09/17
NOX NOX CEO Interview explains recent Brain Cancer Announcement
04/09/17
NOX Appendix 4E and Audited Financial Statements
31/08/17PRICE SENSITIVE
NOX Corporate Governance Statement - Appendix 4G
31/08/17
NOX Corporate Governance Statement
31/08/17
NOX Important Brain Cancer Findings for NOX66 Program
29/08/17PRICE SENSITIVE
NOX Reinstatement to Official Quotation
24/08/17PRICE SENSITIVE
NOX Noxopharm raises $5.5 million to advance clinical program
24/08/17PRICE SENSITIVE
NOX Suspension from Official Quotation
23/08/17PRICE SENSITIVE
NOX Trading Halt Request
21/08/17
NOX Trading Halt
21/08/17PRICE SENSITIVE
NOX NOX Corporate Presentation ahead of Conference
08/08/17
NOX Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
NOX NOX Research Report prepared by APP Securities
27/07/17
NOX CEO Interview with FNN - Singapore and HK Roadshow
25/07/17
NOX New Corporate Presentation
25/07/17
NOX Noxopharm provides update on NOX66 Clinical Trial Program
06/07/17PRICE SENSITIVE
NOX Idronoxil data provides hope to treat secondary brain cancer
19/06/17PRICE SENSITIVE
NOX NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment
05/06/17PRICE SENSITIVE
NOX New Corporate Presentation
30/05/17
NOX St Vincents Cancer Study to Commence-NOX66 and Radiotherapy
29/05/17PRICE SENSITIVE
NOX NOX makes strategic commitment to treatment of rare cancers
24/05/17PRICE SENSITIVE
NOX Noxopharm Mid Year Investor Briefings
18/05/17
NOX Market Guidance for Next Six Months
02/05/17PRICE SENSITIVE
NOX Appendix 4C - quarterly
27/04/17PRICE SENSITIVE
NOX FNN Interview with NOX CEO Explaining Idronoxil-C Discovery
10/04/17
NOX NOX Files Patent Application on 'Smart' Idronoxil
10/04/17PRICE SENSITIVE
NOX Appendix 3B
03/04/17
NOX NOX and Monash Uni Collaboration Receives Federal Grant
27/03/17PRICE SENSITIVE
NOX Noxopharm and UNSW combine on stroke project
16/03/17PRICE SENSITIVE
NOX Gold Coast Qld Mid-Year Briefing Details
10/03/17
NOX Notification of Release of Restricted Securities Escrow
07/03/17
NOX NOX researching rare Abscopal Response
03/03/17PRICE SENSITIVE
NOX Appendix 4D and Half Year Accounts
24/02/17PRICE SENSITIVE
NOX NOX Presentation and Interview ASX The CEO Sessions
24/02/17
NOX Updated Share Trading Policy
23/02/17
NOX ASX CEO Presentation Feb 2017
21/02/17
NOX Upcoming Events and Presentations
15/02/17
NOX Change of Principal Place of Business
03/02/17
NOX Brain Cancer Study Commences
01/02/17PRICE SENSITIVE
NOX First NOX66 Clinical Trial to Commence
31/01/17PRICE SENSITIVE
NOX Appendix 4C - quarterly
30/01/17PRICE SENSITIVE
NOX Appointment of New Company Secretary
16/01/17
NOX Appendix 3B
09/01/17
NOX Change in substantial holding
20/12/16
NOX Change of Director's Interest Notice - ID
20/12/16
NOX Change of Director's Interest Notice - GK
20/12/16
NOX Market Capitalisation - further update
20/12/16
NOX Appendix 3B
20/12/16
NOX Market Capitalisation Update
19/12/16
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
9.9¢ 		Change
0.000(0.00%) 		Mkt cap ! $29.22M
Open High Low Value Volume
10.0¢ 10.5¢ 9.9¢ $4.773K 48.10K

Buyers (Bids)

No. Vol. Price($)
1 20574 9.9¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 38542 2
View Market Depth
Last trade - 16.10pm 29/11/2024 (20 minute delay) ?
Last
9.9¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
11.0¢ 11.0¢ 9.9¢ 59613
Last updated 15.48pm 29/11/2024 ?
NOX (ASX) Chart

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher Vitrafy Life Sciences Limited (ASX:VFY) has defied this month’s odds to become the only newly-listed Australian company to survive a surprisingly rough November (for newcomers, at least) without sagging below its IPO price.The cryopreservation biotech did give some back on Friday,...
Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia New Zealand’s Reserve Bank has taken a bold step, slashing rates by 50 basis points to 4.25% @ its third cut in just four months. Meanwhile, the Reserve Bank of Australia holds firm at 4.35%, its highest rate in over a decade.This stark policy divergence highlights contrasting glo...
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.